AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39529139 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement intervention in intervention stores
Number of subjects: 0
Study 39529169 — intervention group
Group type: EXPERIMENTAL
Intervention: Iparomlimab (200 mg or 3 mg/kg for patients with body weight < 40 kg, IV, Q3W) until disease progression, intolerable toxicities, withdrawal of consent, death, or up to 2 years.
Number of subjects: 120
Study 39529175 — intervention group
Group type: EXPERIMENTAL
Intervention: Sobriety Treatment and Recovery Teams (START)
Number of subjects: 17
Study 39529175 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaboration strategies (e.g., staff co-location, communication quality)
Number of subjects: 17
Study 39529175 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of third-party resource support
Number of subjects: 17
Study 39529175 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of communication quality
Number of subjects: 17
Study 39529188 — intervention group
Group type: EXPERIMENTAL
Intervention: Lethal means counseling (LMC) plus 2 cable-style gun locks
Number of subjects: 200
Study 39529188 — intervention group
Group type: COMPARATOR
Intervention: Lethal means counseling (LMC)
Number of subjects: 200
Study 39529199 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS) delivered to the left dorsolateral prefrontal cortex (LDLPFC) once daily for 10 consecutive workdays, with parameters of 120% resting motor threshold, 50 Hz bursts repeated at 5 Hz, 600 pulses per session (total duration 3 min 9 s)
Number of subjects: 0
Study 39529199 — intervention group
Group type: COMPARATOR
Intervention: Sham iTBS
Number of subjects: 0
Study 39529317 — intervention group
Group type: EXPERIMENTAL
Intervention: Acar's uterine compressive atony sutures
Number of subjects: 22
Study 39529482 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.4 μg/kg over 10 min, followed by 0.4 μg/kg/h continuous infusion)
Number of subjects: 45
Study 39529482 — intervention group
Group type: COMPARATOR
Intervention: Control (no dexmedetomidine)
Number of subjects: 45
Study 39529711 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (Step Away) for reduced drinking
Number of subjects: 0
Study 39529939 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose multistrain probiotic mix (Sinquanon)
Number of subjects: 564
Study 39529939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 564
Study 39530130 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR4640
Number of subjects: 0
Study 39530130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39530262 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete resection of HFO area
Number of subjects: 160
Study 39530262 — intervention group
Group type: COMPARATOR
Intervention: Not completely resected HFO area
Number of subjects: 160
Study 39530262 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete HFO area resection
Number of subjects: 160
Study 39530262 — intervention group
Group type: COMPARATOR
Intervention: Resected volume as predictor
Number of subjects: 160
Study 39530465 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized nutrition and exercise intervention (high-protein diet with daily protein supplementation, functional training with strength and aerobic exercises)
Number of subjects: 14
Study 39530465 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 14
Study 39530534 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Number of subjects: 34
Study 39530534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 39530558 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 480 mg intravenously every 4 weeks up to 6 months
Number of subjects: 30
Study 39530558 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 30
Study 39530574 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin 1.25 mg/kg (Days 1, 8, and 15)
Number of subjects: 40
Study 39530624 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil plus XB2001
Number of subjects: 0
Study 39530624 — intervention group
Group type: COMPARATOR
Intervention: Trifluridine/tipiracil
Number of subjects: 0
Study 39530627 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg tarlatamab
Number of subjects: 0
Study 39530627 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg tarlatamab
Number of subjects: 0
Study 39531039 — intervention group
Group type: EXPERIMENTAL
Intervention: GDM group (n=22)
Number of subjects: 37
Study 39531039 — intervention group
Group type: COMPARATOR
Intervention: non-GDM group (n=15)
Number of subjects: 37
Study 39531116 — intervention group
Group type: EXPERIMENTAL
Intervention: CAYA intervention (nurse-led HIV prevention)
Number of subjects: 450
Study 39531116 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait-list)
Number of subjects: 450
Study 39531161 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 0
Study 39531161 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 0
Study 39531161 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 0
Study 39531161 — intervention group
Group type: COMPARATOR
Intervention: Comparator (placebo or active comparator)
Number of subjects: 0
Study 39531233 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored video
Number of subjects: 125
Study 39531233 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic video
Number of subjects: 125
Study 39531233 — intervention group
Group type: EXPERIMENTAL
Intervention: Gift card incentive
Number of subjects: 125
Study 39531233 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary incentives (adjusted for trust)
Number of subjects: 125
Study 39531233 — intervention group
Group type: COMPARATOR
Intervention: Control group (ink pen incentive)
Number of subjects: 125
Study 39531231 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Therapy (BCBT)
Number of subjects: 96
Study 39531231 — intervention group
Group type: COMPARATOR
Intervention: Present-Centered Therapy (PCT)
Number of subjects: 96
Study 39531231 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BCBT and PCT
Number of subjects: 96
Study 39531274 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrive clinical pathway
Number of subjects: 0
Study 39531274 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 39531369 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25μg
Number of subjects: 10355
Study 39531369 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy (FF/VI 100/25μg or UMEC/VI 62.5/25μg)
Number of subjects: 10355
Study 39531391 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety in Dementia (SiD) decision aid
Number of subjects: 500
Study 39531391 — intervention group
Group type: COMPARATOR
Intervention: Web-based information control
Number of subjects: 500
Study 39531423 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 400 mg every 6 weeks
Number of subjects: 101
Study 39531433 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote social conversations with research staff over 20-minute video or telephone calls three times per week for 4 weeks
Number of subjects: 196
Study 39531433 — intervention group
Group type: COMPARATOR
Intervention: Passive control condition for 4 weeks
Number of subjects: 196
Study 39531687 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness (measured by FFMQ-15)
Number of subjects: 0
Study 39531689 — intervention group
Group type: EXPERIMENTAL
Intervention: Balovaptan
Number of subjects: 29
Study 39531689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 39531903 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab plus carboplatin-paclitaxel
Number of subjects: 118
Study 39531903 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus carboplatin-paclitaxel
Number of subjects: 118
Study 39531997 — intervention group
Group type: EXPERIMENTAL
Intervention: Unblinded continuous vital sign monitoring with nursing alerts
Number of subjects: 250
Study 39531997 — intervention group
Group type: COMPARATOR
Intervention: Blinded continuous vital sign monitoring
Number of subjects: 250
Study 39532185 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin (GemCis)
Number of subjects: 101
Study 39532185 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine (CAP)
Number of subjects: 101
Study 39532185 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA positivity before ACT
Number of subjects: 101
Study 39532185 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA on-ACT at 12 weeks from C1D1
Number of subjects: 101
Study 39532185 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA on-ACT at 24 weeks from C1D1
Number of subjects: 101
Study 39532185 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA anytime post-surgery
Number of subjects: 101
Study 39532185 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA-negative patients
Number of subjects: 101
Study 39532238 — intervention group
Group type: EXPERIMENTAL
Intervention: Education + automated digital reminders + individualized feedback
Number of subjects: 268
Study 39532238 — intervention group
Group type: COMPARATOR
Intervention: Education + automated digital reminders
Number of subjects: 268
Study 39532238 — intervention group
Group type: EXPERIMENTAL
Intervention: Two telehealth problem-solving sessions with an interventionist
Number of subjects: 268
Study 39532313 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare providers' identification of hazards in the home setting for adolescents with brain injury
Number of subjects: 0
Study 39532313 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazard Priority Matrix Activity
Number of subjects: 0
Study 39532313 — intervention group
Group type: EXPERIMENTAL
Intervention: Thematic analysis of hazards
Number of subjects: 0
Study 39532348 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised transfusion strategy (prescription of RBCT restricted to patients with Hb ≤9.0 g/dL and oxygen extraction ratio)
Number of subjects: 0
Study 39532348 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention group (restrictive approach)
Number of subjects: 0
Study 39532350 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen
Number of subjects: 0
Study 39532350 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39532363 — intervention group
Group type: EXPERIMENTAL
Intervention: Social robot as cotherapist during 9 weekly sessions (B)
Number of subjects: 8
Study 39532363 — intervention group
Group type: COMPARATOR
Intervention: Baseline without the robot during 4 weekly sessions (A)
Number of subjects: 8
Study 39532363 — intervention group
Group type: COMPARATOR
Intervention: Follow-up without the robot during 4 weekly sessions (C)
Number of subjects: 8
Study 39532375 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab monotherapy
Number of subjects: 453
Study 39532375 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 453
Study 39532780 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocatinlimab
Number of subjects: 267
Study 39532780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study 39532835 — intervention group
Group type: EXPERIMENTAL
Intervention: Entinostat 5 mg orally once weekly for 14-day lead-in, followed by entinostat and nivolumab (PD1 inhibitor)
Number of subjects: 27
Study 39532835 — intervention group
Group type: EXPERIMENTAL
Intervention: Entinostat and nivolumab
Number of subjects: 27
Study 39532861 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S vaccine
Number of subjects: 42
Study 39532861 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralizing antibody titer
Number of subjects: 42
Study 39532861 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Spike binding antibody concentration
Number of subjects: 42
Study 39532934 — intervention group
Group type: COMPARATOR
Intervention: ICF core set for post-acute musculoskeletal conditions (Polish sample)
Number of subjects: 840
Study 39532934 — intervention group
Group type: EXPERIMENTAL
Intervention: ICF core set for post-acute musculoskeletal conditions (Spanish sample)
Number of subjects: 840
Study 39532934 — intervention group
Group type: EXPERIMENTAL
Intervention: ICF components 'Body Functions' and 'Environmental Factors'
Number of subjects: 840
Study 39532934 — intervention group
Group type: EXPERIMENTAL
Intervention: ICF entity 'b280 Sensation of pain'
Number of subjects: 840
Study 39532934 — intervention group
Group type: EXPERIMENTAL
Intervention: ICF entity 'e225 Climate'
Number of subjects: 840
Study 39532934 — intervention group
Group type: EXPERIMENTAL
Intervention: ICF entity 'd430 Lifting and carrying objects'
Number of subjects: 840
Study 39532934 — intervention group
Group type: COMPARATOR
Intervention: ICF entity 'd450 Walking'
Number of subjects: 840
Study 39533001 — intervention group
Group type: EXPERIMENTAL
Intervention: Remdesivir
Number of subjects: 185
Study 39533001 — intervention group
Group type: COMPARATOR
Intervention: Control (standard of care alone or with hydroxychloroquine)
Number of subjects: 185
Study 39533015 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor (n=24, 39.3%)
Number of subjects: 877
Study 39533015 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-plerixafor-based regimens (n=37, 60.7%)
Number of subjects: 877
Study 39533015 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage auto-HCT (PM patients)
Number of subjects: 877
Study 39533015 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS) for PM patients
Number of subjects: 877
Study 39533115 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicadrostat (10 mg)
Number of subjects: 11000
Study 39533115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11000
Study 39533185 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Laryngoscopy (VL)
Number of subjects: 9881
Study 39533185 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentax Airway Scope (AWS)
Number of subjects: 9881
Study 39533185 — intervention group
Group type: COMPARATOR
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 9881
Study 39533186 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofol (N=40)
Number of subjects: 78
Study 39533186 — intervention group
Group type: COMPARATOR
Intervention: Propofol (N=38)
Number of subjects: 78
Study 39533194 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofol combined with alfentanil
Number of subjects: 217
Study 39533194 — intervention group
Group type: COMPARATOR
Intervention: Propofol combined with alfentanil
Number of subjects: 217
Study 39533204 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF on day 7 after chemotherapy
Number of subjects: 160
Study 39533204 — intervention group
Group type: COMPARATOR
Intervention: PEG-rhG-CSF on day 3 after chemotherapy
Number of subjects: 160
Study 39533248 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal education sessions
Number of subjects: 140
Study 39533248 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antenatal education)
Number of subjects: 140
Study 39533250 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-cTB plus systematic biopsy (SB)
Number of subjects: 380
Study 39533250 — intervention group
Group type: COMPARATOR
Intervention: Routine cTB plus SB
Number of subjects: 380
Study 39533250 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-cTB
Number of subjects: 380
Study 39533250 — intervention group
Group type: COMPARATOR
Intervention: cTB
Number of subjects: 380
Study 39533260 — intervention group
Group type: EXPERIMENTAL
Intervention: eSyM, an electronic health record-integrated, ePRO-based symptom management program
Number of subjects: 0
Study 39533260 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal strategies
Number of subjects: 0
Study 39533260 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall SIMPRO strategies
Number of subjects: 0
Study 39533271 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisis Response Plan
Number of subjects: 82
Study 39533271 — intervention group
Group type: COMPARATOR
Intervention: Self-guided Safety Planning
Number of subjects: 82
Study 39533310 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital foot examinations using a Clinical Decision Support System
Number of subjects: 100
Study 39533310 — intervention group
Group type: COMPARATOR
Intervention: Traditional foot examinations
Number of subjects: 100
Study 39533330 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop automatic control of the inspiratory fraction of oxygen (FiO)
Number of subjects: 0
Study 39533330 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 0
Study 39533349 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous upadacitinib
Number of subjects: 420
Study 39533349 — intervention group
Group type: COMPARATOR
Intervention: Placebo to upadacitinib
Number of subjects: 420
Study 39533349 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (continuous upadacitinib and placebo to upadacitinib)
Number of subjects: 420
Study 39533349 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Number of subjects: 420
Study 39533363 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentiation warm-up protocol with jumps combined with sprints with change of direction
Number of subjects: 17
Study 39533363 — intervention group
Group type: COMPARATOR
Intervention: Usual warm-up program
Number of subjects: 17
Study 39533408 — intervention group
Group type: EXPERIMENTAL
Intervention: EAA + omega-3 fatty acids
Number of subjects: 30
Study 39533408 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 30
Study 39533412 — intervention group
Group type: EXPERIMENTAL
Intervention: ePROMs monitoring
Number of subjects: 260
Study 39533412 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 260
Study 39533414 — intervention group
Group type: EXPERIMENTAL
Intervention: 45-min nap during simulated night shift work
Number of subjects: 10
Study 39533414 — intervention group
Group type: COMPARATOR
Intervention: No-nap condition during simulated night shift work
Number of subjects: 10
Study 39533424 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of traditional care with modern healthcare systems
Number of subjects: 510
Study 39533424 — intervention group
Group type: COMPARATOR
Intervention: Control group (no integration of traditional care)
Number of subjects: 510
Study 39533437 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive strategies for timely treatment adoption
Number of subjects: 0
Study 39534099 — intervention group
Group type: EXPERIMENTAL
Intervention: Livmoniplimab monotherapy (3mg to 1500mg Q2W)
Number of subjects: 57
Study 39534099 — intervention group
Group type: EXPERIMENTAL
Intervention: Livmoniplimab in combination with budigalimab (500mg Q4W)
Number of subjects: 57
Study 39534205 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney BEAM physical activity digital health intervention (DHI)
Number of subjects: 340
Study 39534205 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 340
Study 39534248 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) session embedded in physical education or physical activity lessons, 6 to 10 minutes, five days a week for 12 weeks
Number of subjects: 8
Study 39534248 — intervention group
Group type: COMPARATOR
Intervention: Usual activities (control group)
Number of subjects: 8
Study 39534354 — intervention group
Group type: EXPERIMENTAL
Intervention: QFR-guided CABG (n=69)
Number of subjects: 188
Study 39534354 — intervention group
Group type: COMPARATOR
Intervention: CAG-guided CABG (n=119)
Number of subjects: 188
Study 39534354 — intervention group
Group type: EXPERIMENTAL
Intervention: QFR-guided CABG
Number of subjects: 188
Study 39534354 — intervention group
Group type: COMPARATOR
Intervention: CAG-guided CABG
Number of subjects: 188
Study 39534390 — intervention group
Group type: EXPERIMENTAL
Intervention: PEMF therapy plus eccentric exercise
Number of subjects: 65
Study 39534390 — intervention group
Group type: COMPARATOR
Intervention: Sham group (eccentric exercise only)
Number of subjects: 65
Study 39534453 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) experience
Number of subjects: 27
Study 39534453 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study 39534481 — intervention group
Group type: EXPERIMENTAL
Intervention: bimekizumab 160 mg every 4 weeks
Number of subjects: 0
Study 39534593 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrageenan- and sorbitol-containing nasal spray (CS)
Number of subjects: 41
Study 39534593 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (SS)
Number of subjects: 41
Study 39534856 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 0
Study 39534856 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 0
Study 39534856 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline systemic inflammation)
Number of subjects: 0
Study 39534972 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole 2 or 3 mg/day
Number of subjects: 259
Study 39535306 — intervention group
Group type: EXPERIMENTAL
Intervention: Crovalimab
Number of subjects: 504
Study 39535306 — intervention group
Group type: COMPARATOR
Intervention: Eculizumab
Number of subjects: 504
Study 39535462 — intervention group
Group type: EXPERIMENTAL
Intervention: Tozorakimab 60 mg
Number of subjects: 148
Study 39535462 — intervention group
Group type: EXPERIMENTAL
Intervention: Tozorakimab 300 mg
Number of subjects: 148
Study 39535462 — intervention group
Group type: EXPERIMENTAL
Intervention: Tozorakimab 600 mg
Number of subjects: 148
Study 39535462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 39535568 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional near-infrared spectroscopy (fNIRS)
Number of subjects: 604
Study 39535568 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus somatosensory evoked potentials (VSEP)
Number of subjects: 604
Study 39535568 — intervention group
Group type: EXPERIMENTAL
Intervention: Known risk factors (ApoE4 risk alleles, dysosmia, poor cognitive performance)
Number of subjects: 604